- Polyrizon Ltd. has completed a major manufacturing upscaling milestone for its PL-14 nasal-spray platform, transitioning from small-batch to larger-scale production.
- The validated process will support clinical trial material production ahead of a planned clinical trial in 2026.
Polyrizon Ltd. has announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform based on the company’s Capture & Contain technology. The achievement marks a key step in preparing for upcoming clinical and regulatory activities and potential future commercial readiness.
The company and its manufacturing partner have moved from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to validate essential parameters of the PL-14 formulation. According to the announcement, the successful run demonstrates that PL-14 can be produced at higher batch volumes while maintaining required quality standards. The process will support production of clinical trial material for a study expected to begin in 2026 and is aligned with USA and European regulatory requirements.
Polyrizon stated that the completed batch validates the company’s manufacturing strategy and positions it to progress towards subsequent batches required for clinical material production.
“This successful batch production is a testament to the strength of our C&C technology and the expertise of our CDMO partner.”
Tomer Izraeli, Chief Executive Officer of Polyrizon
PL-14 is an intranasal protective spray designed to create a moisturising barrier inside the nasal cavity, with the aim of trapping, isolating and neutralising airborne allergens before they reach the mucosa. The formulation is based on Polyrizon’s proprietary bio-adhesive technology and is intended to deliver extended protection as a non-pharmacological option for allergy sufferers.
